Adipose-derived Mesenchymal Stem Cells in Osteoarthritis

Summary

This phase I/II study will enroll 100 subjects with mild to moderate osteoarthritis of the hip/knee/glenohumeral joints will be enrolled according to strict inclusion and exclusion criteria. Subjects will receive a single dose of at least 10 million of autologous Adipose-derived Mesenchymal Stem Cells (ADMCS) every three months for 12 months (maximum four doses in total and at least 40 million of ADMCS in total) via ultrasound guided intra-articular injection.

Timeline

Start

2019-04-05

Primary completion

2020-03-01

Completion

2022-03-20

Drugs

Indications